

- Our novel statistical modeling approach can be used to adjust for trial heterogeneity in order to make informed comparisons between treatments when no head-to-head trial is available.
- By adjusting for known or suspected treatment modifiers and controlling for differences in patient characteristics across the placebo-controlled trials of oral therapies for multiple sclerosis, our study provides the most informed comparison of fingolimod, dimethyl fumarate and teriflunomide.
- Our study predicts that patients treated with fingolimod have a significantly higher probability of achieving no evidence of disease activity status for some measures compared with those treated with dimethyl fumarate or teriflunomide.
- The modeling strategy applied in our study offers clear advantages over unadjusted comparisons, which can be subject to bias.
- However, the results here cannot be compared with evidence from a randomized clinical trial and need to be interpreted with caution owing to the assumptions inherent in any modeling study.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Novartis Pharma AG. Medical writing assistance for this study was provided by Oxford PharmaGenesis and was funded by Novartis Pharma AG. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).